020515 diabetes pharm Flashcards
how is insulin secretion controlled?
stimulators: GLUCOSE (taken up by GLUT2 receptor in beta cell) amino acids fatty acids indirect (GH or cortisol)
inhibitors:
somatostatin (paracrine effect within pancreas)
effect of glucagon
increases gluconeogenesis in liver
tissue release of glucose, fatty acids, ketoacids into circulation
glucagon-like peptides (GLPs)
secreted from gut in response to feeding
acute-increases insulin response to glucose
chronic-increases beta cell mass
the injectable form of insulin has what structure
no C peptide
insulin formulations
regular insulin NPH insulin (colloidal suspension that's intermediate acting) pre-mixed insulin-mixtures of NPH and short acting
advantage of insulin lispro over regular insulin
insulin lispro is shorter acting. regular insulin outlasts the calories of the meal, so you can get hypoglycemia
long acting insulin analogs
insulin glargine (24-36 hr duration-the longest) insulin detemir (long acting due to self association in the subcu injection site AND by binding to albumin in blood stream)
short acting insulin analogs
lispro insulin
insulin aspart
insulin glulisine
goal for diabetic fasting glucose
70-130
side effects of insulin
hypoglycemia insulin allergy lipoatrophy lipohypertrophy insulin edema weight gain-if you don't watch diet
sulfonylureas
stimulate insulin secretion by pancreas by inactivating K channel in beta cell (this causes depolarization, which causes influx of Ca into cell, which causes insulin to be released)
glipizide
glyburide
glimepiride
side effects of sulfonylureas
HYPOGLYCEMIA
rashes
GI side effects
drug interactions
metformin’s MOA
makes liver more sensitive to insulin–principal result is decreasing hepatic gluconeogenesis
side effects of metformin
GI
most serious: lactic acidosis (don’t prescribe metformin in pts with RENAL INSUFFICIENCY b/c can lead to lactic acidosis. also don’t use in pts with liver dysfxn)
thiazolidinediones’ MOA
make peripheral tissues such as FAT and MUSCLE more sensitive to insulin (PPAR receptor agonists)